Clinical Trials on Unipolar Major Depression in Argentina

Total 50 results

AstraZeneca

Completed

Prevalence and Risk Factors in Unipolar Depression Patients Without Remission After One Antidepressant Trial (PANTHER)

Non-psychotic Unipolar Major Depression

Argentina
Sanofi

Completed

A Study of SR58611A in the Prevention of Depression Relapse in Patients With Major Depressive Disorder (CALYPSO)

Depressive Disorder | Major Depression

France, Poland, Romania, Russian Federation, Bulgaria, Serbia, Slovakia, Czech Republic, Mexico, Argentina, Croatia, Finland, South Africa
Sanofi

Completed

An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder

Major Depressive Disorder

United States, France, Sweden, Mexico, Argentina, Finland
Sanofi

Completed

Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive Disorder

Major Depressive Disorders

Russian Federation, Spain, Singapore, Taiwan, Tunisia, Argentina, Chile, Hong Kong, Morocco, South Africa, Greece
Sanofi

Completed

An Eight-Week Study Evaluating the Efficacy of Two Fixed Doses (250 mg Twice Daily and 100 mg Twice Daily) of SSR149415 in Patients With Major Depressive Disorder (LENA)

Depressive Disorder

Canada, Russian Federation, Bulgaria, Mexico, Argentina, Chile, Croatia
Intra-Cellular Therapies, Inc.

Active, not recruiting

Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Major Depressive Disorder

United States, Bulgaria, Germany, Poland, Finland, Sweden, Argentina
Eli Lilly and Company

Completed

A Study in the Treatment of Children and Adolescents With Major Depressive Disorder

Major Depressive Disorder

Mexico, United States, Argentina, Canada
AstraZeneca

Completed

Efficacy and Safety of Quetiapine Versus Quetiapine Plus Lithium in Bipolar Depression (QUALITY)

Acute Bipolar Depression

Brazil, Mexico, Peru, Turkey, Argentina, Chile, Venezuela, Colombia, Guatemala
AstraZeneca

Completed

Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder

Major Depressive Disorder

Russian Federation, United States, Estonia, Ukraine, Finland, Argentina
Eli Lilly and Company

Completed

A Study in Prevention of Re-emergence of Depression Symptoms

Major Depressive Disorder

United States, Germany, Italy, Turkey, Russian Federation, Korea, Republic of, Greece, France, Croatia, Romania, Spain, Argentina, Puerto Rico, Belgium, Mexico, Slovakia
H. Lundbeck A/S

Completed

Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression (VIVRE)

Major Depressive Disorder

Spain, Czechia, Slovakia, Estonia, Sweden, Argentina, Belgium, Bulgaria, Latvia, Mexico, Russian Federation, Ukraine
Shire

Completed

SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Major Depressive Disorder

United States, Chile, Australia, Argentina, United Kingdom
Novartis Pharmaceuticals

Terminated

Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent

Major Depressive Disorder With Suicidal Ideation With Intent

Taiwan, Spain, Germany, Netherlands, Turkey, Mexico, United States, Malaysia, Poland, Canada, Japan, Russian Federation, Argentina, Brazil
AstraZeneca
Targacept Inc.

Completed

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.

Major Depressive Disorder

Croatia, Brazil, Bulgaria, France, Poland, Russian Federation, South Africa, Hungary, Romania, Ukraine, Argentina, Chile, Slovakia, Colombia, Germany, Serbia, Spain
Janssen-Cilag Ltd.

Active, not recruiting

A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment (ESCAPE-LTE)

Depressive Disorder, Major

Taiwan, Turkey, Malaysia, Germany, Czechia, Korea, Republic of, Poland, Hungary, Argentina, Belgium, Bulgaria, Finland, Greece, South Africa
Eli Lilly and Company

Completed

A Study in Adult Patients With Major Depressive Disorder

Depressive Disorder, Major

United States, Finland, Poland, Russian Federation, Argentina
Janssen Research & Development, LLC

Terminated

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

Depressive Disorder, Major

United States, Korea, Republic of, Malaysia, Poland, Finland, Chile, Argentina, Slovakia, Ukraine, Denmark
GlaxoSmithKline

Completed

Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD)

Depressive Disorder, Major

Belgium, Peru, Argentina, Chile, Costa Rica, Slovakia, Italy, Germany, Poland, Spain, Sweden
Boehringer Ingelheim

Completed

A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression

Depressive Disorder, Major

Spain, United States, Canada, Germany, Japan, Argentina, Hungary, France, Australia, Bulgaria, Czechia, Poland, Russian Federation, Slovakia
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women

Depressive Disorder | Depression | Depressive Disorder, Major

Colombia, Mexico, United States, Peru, Chile, Argentina
Janssen-Cilag International NV

Completed

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder (ESCAPE-TRD)

Depressive Disorder, Major

Israel, Hungary, Korea, Republic of, Taiwan, Portugal, Turkey, Germany, Malaysia, Denmark, Bulgaria, Czechia, Belgium, Poland, Brazil, Netherlands, Argentina, Finland, Greece, South Africa, Austria, Kazakhstan, Norway, Sweden, United...
Janssen Research & Development, LLC

Completed

A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

Depressive Disorder, Major

United States, Belgium, Czechia, Ukraine, Poland, Malaysia, Serbia, Bulgaria, Argentina, Lithuania, Slovakia, Russian Federation, Canada, United Kingdom, Latvia
Janssen Research & Development, LLC

Recruiting

A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT)

Depressive Disorder, Major

United States, Korea, Republic of, Taiwan, Slovakia, Spain, Bulgaria, Poland, Belgium, Argentina, Czechia, Hungary, South Africa, Sweden, Italy, France, Australia, China, Brazil, Portugal
Janssen Research & Development, LLC

Completed

54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide (Aspire II)

Depressive Disorder, Major

United States, Belgium, Canada, Poland, France, Spain, Brazil, Lithuania, Czechia, Austria, Argentina, Turkey
Janssen Research & Development, LLC

Recruiting

A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) (VENTURA-RWE)

Depressive Disorder, Major

United States, Korea, Republic of, Spain, Argentina, United Kingdom, Sweden, Italy, Germany, France, Canada, Brazil
Janssen Research & Development, LLC

Completed

Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants

Depressive Disorder | Psychotic Disorders | Schizophrenia | Bipolar Disorder

United States, Belgium, Germany, Spain, Argentina, Brazil, Bulgaria
Janssen Research & Development, LLC

Recruiting

A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy (VENTURA-1)

Anhedonia | Depressive Disorder, Major

United States, Spain, Bulgaria, Italy, Poland, Belgium, Argentina, Czechia, Hungary, Sweden, Brazil, Australia, Portugal
Universidad Nacional de Rosario

Completed

Mirtazapine Reduces ICD Shocks in ICD Patients With Depression and Anxiety

Depression | Anxiety

Argentina
Janssen Research & Development, LLC

Recruiting

A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy (VENTURA-2)

Anhedonia | Depressive Disorder, Major

Korea, Republic of, United States, China, Taiwan, Slovakia, Brazil, Poland, Argentina, Bulgaria, Czechia, South Africa, Canada, United Kingdom, France
Janssen Research & Development, LLC

Completed

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression (SUSTAIN-2)

Treatment-resistant Depression

United States, Australia, France, United Kingdom, Belgium, Germany, Taiwan, Spain, Argentina, Mexico, Poland, Bulgaria, Malaysia, South Africa, Turkey, Finland, Korea, Republic of, Brazil, Austria, Sweden, Lithuania
Eli Lilly and Company

Completed

A Study in Relapse Prevention of Treatment-Resistant Depression

Treatment Resistant Depression

United States, Argentina, Russian Federation, South Africa, India, Turkey, Puerto Rico, Mexico
Takeda

Terminated

Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder

Acute Depressive Episode

United States, Argentina, Chile, Colombia, Mexico
Janssen Research & Development, LLC

Completed

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression (SUSTAIN-3)

Depressive Disorder, Treatment-Resistant

United States, France, Poland, United Kingdom, Belgium, Germany, Taiwan, Spain, Argentina, Mexico, Bulgaria, Malaysia, South Africa, Turkey, Canada, Korea, Republic of, Brazil, Estonia, Hungary, Lithuania, Slovakia, Sweden, Czechia, A... and more
Cephalon

Completed

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Depression

Spain, United States, Poland, Canada, South Africa, Argentina, Australia, Bulgaria, France, Ukraine
Cephalon

Completed

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Depression

United States, Argentina, Brazil, Bulgaria, Croatia, Finland, Germany, Hungary, Italy, Poland, Serbia, Slovakia, South Africa, Ukraine
Bristol-Myers Squibb

Completed

Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression

Depression

Italy, South Africa, United States, Australia, Argentina, Canada, Austria, France, Spain, India, Puerto Rico, United Kingdom
Cephalon

Terminated

Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Depression

United States, Argentina, Australia, Brazil, Bulgaria, Canada, Croatia, France, Germany, Hungary, Italy, Poland, Serbia, Slovakia, South Africa, Spain, Ukraine
Bristol-Myers Squibb

Terminated

Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

Depression

France, South Africa, Sweden, United States, Australia, Italy, Argentina, Austria, Spain, Finland, India, Puerto Rico
Merck KGaA, Darmstadt, Germany

Completed

To Identify and Evaluate the Predictive Factors for Depression in Patients Diagnosed With Multiple Sclerosis

Multiple Sclerosis

Argentina
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of Aripiprazole in the Treatment of Patients With Acute Symptoms of Bipolar Disorder

Bipolar I Disorder

United States, Argentina
Daniel Serrani Azcurra
Zarebski Graciela, Kabanchik Alicia, Marconi Araceli

Recruiting

Multifactorial Approach to Dementia, Multicentric Study

Depression | Dementia of Alzheimer Type | Dementia Frontotemporal | Narcissistic Personality Disorder | Personality Change

Argentina
AstraZeneca

Completed

Quetiapine Fumarate Bipolar Maintenance Monotherapy (SPaRCLe)

Bipolar Disorder

United States, Bulgaria, Peru, Russian Federation, Philippines, Malaysia, Lithuania, Romania, Ukraine, Argentina, Taiwan, Mexico, Thailand, India, Colombia
Janssen-Cilag, S.A.

Completed

Treatment Resistant Depression in America Latina (TRAL)

Depressive Disorder, Treatment-Resistant

Brazil, Argentina, Mexico, Colombia
Takeda

Terminated

Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder

Bipolar Disorder

United States, Argentina, Chile, Colombia, Mexico
Sunovion

Completed

Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex (PERSIST)

Bipolar I Disorder

United States, Croatia, Hungary, Poland, Serbia, Argentina, Japan, France, Slovakia, Australia, Russian Federation, Bulgaria, Chile, Czech Republic
Sunovion

Completed

This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296 (PERSISTExt)

Bipolar I Disorder

United States, Poland, Bulgaria, Japan, Slovakia, Hungary, Russian Federation, Czech Republic, Argentina, Chile, France, Serbia
Alkermes, Inc.

Enrolling by invitation

Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects

Schizophrenia | Bipolar I Disorder

United States, Argentina, Brazil, Colombia, Mexico
Alkermes, Inc.

Recruiting

Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

Schizophrenia | Bipolar I Disorder

United States, Argentina, Mexico, Brazil, Colombia
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation

Spain, Italy, Austria, Netherlands, United Kingdom, Thailand, France, Belgium, China, Germany, Greece, Argentina, Turkey, Malaysia, Portugal, Brazil, United States, Hungary, India
University of Chile
Columbia University

Recruiting

The Covid-19 HEalth caRe wOrkErS (HEROES) Study (HEROES)

Depression | Covid-19 | Anxiety | Mental Health Disorder | SARS-CoV-2 | Stress Disorder

United States, Italy, Argentina, Armenia, Australia, Bolivia, Chile, Costa Rica, Czechia, Germany, Guatemala, Lebanon, Mexico, Netherlands, Nigeria, Puerto Rico, Saudi Arabia, Spain, Tunisia, Turkey, Venezuela

Clinical Trials on Unipolar Major Depression in Argentina

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations